CoChat

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Open access
Tsai, Yihsuan S., Woodcock, Mark G., Azam, Salma H., Thorne, Leigh B., Kanchi, Krishna L., Parker, Joel S., Vincent, Benjamin G., Pecot, Chad V. · 2022 · Journal of Clinical Investigation

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUNDThe KRAS proto-oncogene is among the most frequently mutated genes in cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric inhibitors that covalently bind to KRAS G12C mutations have been approved for use in lung adenocarcinomas. Although responses are observed, they are often short-lived, thus making in-depth characterization of the mechanisms of resistance of paramount importance.METHODSHere, we present a rapid-autopsy case of a patient who had a KRASG12C-mutant lung adenocarcinoma who initially responded to a KRAS G12C inhibitor but then rapidly developed resistance. Using deep-RNA and whole-exome sequencing comparing pretreatment, posttreatment, and matched normal tissues, we uncover numerous mechanisms of resistance to direct KRAS inhibition.RESULTSIn addition to decreased KRAS G12C-mutant allele frequency in refractory tumors, we also found reactivation of the MAPK pathway despite no new mutations in KRAS or its downstream mediators. Tumor cell-intrinsic and non-cell autonomous mechanisms included increased complement activation, coagulation, and tumor angiogenesis, and several lines of evidence of immunologic evasion.CONCLUSIONTogether, our findings reveal numerous mechanisms of resistance to current KRAS G12C inhibitors through enrichment of clonal populations, KRAS-independent downstream signaling, and diverse remodeling of the tumor microenvironment.FUNDINGRichard and Fran Duley, Jimmy and Kay Mann, the NIH, and the North Carolina Biotechnology Center.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci155523

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Rapid acquired resistance to AMG510. (A) Serial cross-sectional tumor dimensions while the patient received AMG510. (B) All samples were acquired either before the patient went on study (pre-AMG510) or during the rapid autopsy 6 weeks after stopping the drug (post-AMG510). All nonadjacent normal tissues were at least 1 cm from the tumor margin and confirmed by a pathologist to be free of tumor. (C) An illustration of the locations of tumors sampled for the study.
Figure 1 Rapid acquired resistance to AMG510. (A) Serial cross-sectional tumor dimensions while the patient received AMG510. (B) All samples were acquired either before the patient went on study (pre-AMG510) or during the rapid autopsy 6 weeks after stopping the drug (post-AMG510). All nonadjacent normal tissues were at least 1 cm from the tumor margin and confirmed by a pathologist to be free of tumor. (C) An illustration of the locations of tumors sampled for the study.CC BY · PubMed Central
Figure 2 Dynamic adaptive cell-intrinsic reprograming and TME remodeling. (A) Nine hundred fifty differentially expressed genes with adjusted P values of less than 0.05 are shown as heatmaps, with 709 upregulated and 241 downregulated after AMG510 treatment. (B) Gene set analysis via GSVA using 189 MsigDB oncogenic signatures identified 38 oncogenic signatures (Padj < 0.05) that were upregulated after AMG510 treatment. (C) GSVA analysis using 50 MsigDB Hallmark gene sets identified 9 signatures (Padj < 0.05) that were differentially expressed, including upregulation in the Coagulation and EMT pathways. (D) GSEA for coagulation, EMT, and fatty acid metabolism.
Figure 2 Dynamic adaptive cell-intrinsic reprograming and TME remodeling. (A) Nine hundred fifty differentially expressed genes with adjusted P values of less than 0.05 are shown as heatmaps, with 709 upregulated and 241 downregulated after AMG510 treatment. (B) Gene set analysis via GSVA using 189 MsigDB oncogenic signatures identified 38 oncogenic signatures (Padj < 0.05) that were upregulated after AMG510 treatment. (C) GSVA analysis using 50 MsigDB Hallmark gene sets identified 9 signatures (Padj < 0.05) that were differentially expressed, including upregulation in the Coagulation and EMT pathways. (D) GSEA for coagulation, EMT, and fatty acid metabolism.CC BY · PubMed Central
Figure 3 Loss of KRASG12C variants and clonal phylogenetic analyses. (A) Total number of mutations detected in each tumor sample. A 2-sided Student’s t test was run to compare mean numbers of single nucleotide variants between pre- and post-AMG510 treatment. (B) KRASG12C mutation allele frequency detected in each sample. Sequenza purity levels are shown for each sample in black. (C) Nonsynonymous mutations detected in 3 or more tumors with mutations expressed in RNA. (D) Representative phylogenetic trees showing potential clonal evolution. Pre- and posttreatment samples are colored in the branches as purple and green, respectively.
Figure 3 Loss of KRASG12C variants and clonal phylogenetic analyses. (A) Total number of mutations detected in each tumor sample. A 2-sided Student’s t test was run to compare mean numbers of single nucleotide variants between pre- and post-AMG510 treatment. (B) KRASG12C mutation allele frequency detected in each sample. Sequenza purity levels are shown for each sample in black. (C) Nonsynonymous mutations detected in 3 or more tumors with mutations expressed in RNA. (D) Representative phylogenetic trees showing potential clonal evolution. Pre- and posttreatment samples are colored in the branches as purple and green, respectively.CC BY · PubMed Central
Figure 4 Tumor immunogenomic and neoantigen features. (A) Immune gene signatures by treatment time point, out of 40 tested signatures. (B) Tumor sample IgH repertoire comparison, by treatment time point. Horn’s modified Morisita overlap index. (C) Tumor sample T cell receptor β chain (TRB) repertoire comparison, by treatment time point. Horn’s modified Morisita overlap index. (D) Intersample predicted neoantigen count overlap between samples, log10 scale. Significance was assessed with the 2-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4 Tumor immunogenomic and neoantigen features. (A) Immune gene signatures by treatment time point, out of 40 tested signatures. (B) Tumor sample IgH repertoire comparison, by treatment time point. Horn’s modified Morisita overlap index. (C) Tumor sample T cell receptor β chain (TRB) repertoire comparison, by treatment time point. Horn’s modified Morisita overlap index. (D) Intersample predicted neoantigen count overlap between samples, log10 scale. Significance was assessed with the 2-sided Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 109

Metadata

Authors
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V.
Affiliations
  • UNC Lineberger Comprehensive Cancer Center (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Pecot, Chad V.
Venue
Journal of Clinical Investigation
Published
2022-02-15
Volume
132
Issue
4
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4205097199
Cited by
103
References
43
Citations by year
2026: 13 · 2025: 25 · 2024: 26 · 2023: 28 · 2022: 11
FWCI
14.51
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA215075,R01CA258451,1R41CA246848)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS G12C, KRAS inhibitors, drug resistance, lung adenocarcinoma, MAPK pathway reactivation, tumor microenvironment, complement activation, coagulation, tumor angiogenesis, clonal populations, allele frequency, autopsy
MeSH terms
Adenocarcinoma of Lung, Humans, Lung Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Amino Acid Substitution, Mutation, Missense, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. https://app.cochat.ai/papers/10.1172/jci155523
The paper
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022). Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. Journal of Clinical Investigation. https://doi.org/10.1172/jci155523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.